3 JPM 2023 roivant Pipeline reflects both ongoing clinical trials and expected upcoming trials. VTAMA has only received FDA approval for psoriasis, not atopic dermatitis. 5 | --- | --- | |----------------------|-----------------| | Psoriasis | $22.3 billion | | Atopic Dermatitis | $12.2 billion | | Crohn's Disease | $9.3 billion | | Ulcerative Colitis | $6.9 billion | | SLE | $3.8 billion | | Rheumatoid Arthritis | $10.2 billion | | | | Indications with active development programs Other indications RVT-3101 ...